CorMedix Inc.

CorMedix Inc. , based in the US, is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products aimed at preventing serious health complications in patients. Founded in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix Inc. develops products aimed at preventing life-threatening diseases, notably in the renal and infectious disease sectors.

The company does not have known subsidiaries or a parent company. CorMedix has primarily operated in the healthcare industry without notable pivots in its business strategy. The founder's history is not publicly detailed. CorMedix Inc.

primarily focuses on developing and commercializing therapeutic products aimed at preventing life-threatening diseases, specifically in the cardiovascular, renal, and infectious disease sectors. The company's flagship product, DefenCath™, is designed to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in patients who require central venous catheters (CVCs) for hemodialysis. By utilizing a combination of taurolidine and heparin, DefenCath™ functions by acting as an antimicrobial and anticoagulant agent, addressing two critical concerns associated with catheter use. CorMedix's products are marketed primarily to healthcare providers and institutions within the United States, as well as select international markets, improving patient outcomes and reducing healthcare costs related to CRBSIs.

The company also collaborates with healthcare professionals, hospitals, and clinics that serve patients undergoing hemodialysis and other related treatments, ensuring its solutions align with clinical needs. CorMedix generates revenue through the sale of its proprietary products, engaging directly with healthcare providers and institutions. Transactions typically involve hospitals and clinics purchasing DefenCath™ in bulk for their hemodialysis units, providing necessary resources to reduce the risks of CRBSIs among patients. The pricing structure is aligned with the value of the product in enhancing patient care and minimizing complications from catheter use.

Additional revenue streams may arise from partnerships with healthcare organizations supporting research and development, as well as potential collaborations with distributors in non-U. S. markets. CorMedix's focus on innovative therapeutic solutions positions it strategically within the healthcare field, addressing essential needs.

CorMedix Inc. plans to expand its market presence by developing new products focused on improving patient care outcomes, though specific product launches and timelines have not been disclosed. The company aims to penetrate additional international markets within the next several years, leveraging recent funding to bolster research and development efforts. Further details on how the latest funding will specifically support these initiatives have not been provided.